HLB Life Science secures 5th state grant to develop medical hemp therapies

HLB Life Science R&D, the research and development subsidiary of HLB, a prominent Korean life sciences conglomerate, has been selected for its fifth government-backed research project this year, according to the firm. Under the project, HLB Life Science R&D is joining a consortium developing next-generation drug candidates from minor cannabinoids as part of Korea’s Gyeongbuk Industrial Hemp Regulatory Free Zone, a special economic zone where companies can legally grow and process hemp for medical and industrial use under relaxed drug-control rules. The 29.6 billion won ($17 million) four-year project, backed by the Ministry of SMEs and Startups and the Office for Government Policy Coordination, will involve HLB Life Science R&D, NeoKenBio, Apack, NBTHEPHARM, TopoLab and INGR, along with the Korea Institute of Science and Technology and the Gyeongbuk Institute for Bio industry, to build a full research pipeline from hemp cultivation to raw material production, preclinical studies and commercialization. The project expands existing industrial hemp research, which has focused mainly on can

Latest News from Korea

Latest Entertainment from Korea

Learn People & History of Korea